A Catalytic, Asymmetric Formal Synthesis of (+)-Hamigeran B

Herschel Mukherjee, Nolan T. McDougal, Scott C. Virgil, and Brian M. Stoltz*

The Arnold and Mabel Beckman Laboratories of Chemical Synthesis, The Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, and the Caltech Center for Catalysis and Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States

stoltz@caltech.edu

Received December 8, 2010

LETTERS 2011 Vol. 13, No. 5 825–827

ORGANIC



A concise asymmetric, formal synthesis of (+)-hamigeran B is reported. A Pd-catalyzed, decarboxylative allylic alkylation, employing a trifluoromethylated derivative of *t*-BuPHOX, is utilized as the enantioselective step to form the critical quaternary carbon center in excellent yield and enantioselectivity. The product is converted in three steps to a late-stage intermediate previously used in the synthesis of hamigeran B.

The hamigerans are a family of molecules isolated from the poecilosclerid sponge *Hamigera tarangaensis* by Bergquist and Fremont (family Anchinoidae, syn. Phorbasidae) in 2000 from the Hen and Chicken Islands off the eastern coast of New Zealand.¹ Hamigeran B (1), which has been of particular interest due to its potent in vitro activity against the P-388 leukemia cell line and against both herpes and polio viruses with little cytotoxicity against the host cells,¹ has a unique tricarbocyclic skeleton possessing a substituted aromatic system fused to a [4.3.0] bicycle containing three contiguous stereocenters and, as such, has received continued attention from synthetic chemists.^{2,3}

Previous syntheses of hamigeran B have utilized a photoinitiated intramolecular [4 + 2] cycloaddition of a hydroxy-*o*-quinodimethane by Nicolaou,⁴ Meyers' aminoalcohol auxiliary by Clive and Wang,⁵ a Pd-catalyzed

⁽¹⁾ Wellington, K. D.; Cambie, R. C.; Ruteledge, P. S.; Bergquist, P. R. J. Nat. Prod. 2000, 63, 79–85.

⁽²⁾ For a review, see: Clive, D. L. J.; Wang, J. Org. Prep. Proced. Int. 2005, 37, 1–35.

⁽³⁾ For leading references on the construction of the core skeleton, see: (a) Mehta, G.; Shinde, H. M. *Tetrahedron Lett.* 2003, 44, 7049–7053.
(b) Sperry, J. B.; Wright, D. L. *Tetrahedron Lett.* 2005, 46, 411–414. (c) Harmata, M.; Zheng, P.; Schreiner, P. R.; Navarro-Vázquez, A. *Angew. Chem., Int. Ed.* 2006, 45, 1966–1971. (d) Madu, C. E.; Seshadri, H.; Lovely, C. J. *Tetrahedron* 2007, 63, 5019–5029. (e) Madu, C. E.; Lovely, C. J. *Org. Lett.* 2007, 9, 4697–4700. (f) Arnáiz, E.; Blanco-Urgoiti, J.; Abdi, D.; Domínguez, G.; Castells, J. P. J. Organomet. Chem. 2008, 693, 2431–2437. (g) Cai, Z.-X.; Harmata, M. *Org. Lett.* 2010, *12*, 5668–5670.

^{(4) (}a) Nicolaou, K. C.; Gray, D.; Tae, J. Angew. Chem., Int. Ed. **2001**, 40, 3675–3678. (b) Nicolaou, K. C.; Gray, D.; Tae, J. Angew. Chem., Int. Ed. **2001**, 40, 3679–3683. (c) Nicolaou, K. C.; Gray, D. L. F.; Tae, J. J. Am. Chem. Soc. **2004**, 126, 613–627.

^{(5) (}a) Clive, D. L. J.; Wang, J. Angew. Chem., Int. Ed. 2003, 42, 3406–3409. (b) Clive, D. L. J.; Wang, J. Tetrahedron Lett. 2003, 44, 7731–7733.
(c) Clive, D. L. J.; Wang, J. J. Org. Chem. 2004, 69, 2773–2784.

Scheme 1. Retrosynthetic Analysis of (+)-Hamigeran B



asymmetric allylic alkylation followed by an intramolecular lar Heck reaction by Trost,⁶ and an intramolecular Rhmediated C–H insertion of a α -aryl– α -diazoketone followed by a Friedel–Crafts cyclization by Taber and Tian⁷ in the construction of the carbocyclic core. Most recently, Miesch and co-workers performed a racemic total synthesis in which an intramolecular, alkynylogous Mukiyama aldol reaction was utilized to form the tricyclic core.^{8,9} Importantly, they also showed that the stereochemistry at C(9) of **2** can been used to set the proper relative stereochemistry at C(5) and C(6). Herein, we report a catalytic, asymmetric formal synthesis of (+)-hamigeran B via interception at Miesch and co-workers' enone **2**.

Our retrosynthetic analysis of hamigeran B (Scheme 1) thus focused on efficiently generating the absolute stereochemistry of the all-carbon quaternary stereocenter at C(9) of enone **2**. With the goal of setting this stereocenter via an enantioselective, decarboxylative alkylation,¹⁰ we envisioned first disconnecting the cyclopentene ring of **2** via an aldol condensation to α -allyl tetralone **3**, which could be accessed via the asymmetric allylation chemistry developed within our group,¹¹ from tetralone **4** as the key racemic starting material.

Studies for the enantioselective synthesis of tetralone **3** focused on the asymmetric, decarboxylative allylic alkylation of allyl enol carbonate **5**, available in 91% yield from known tetralone $4^{12,5a,5c}$ (Scheme 2). Preliminary investigation of the alkylation reaction of **5** used 4 mol % of the complex derived from Pd₂(dba)₃ and (*S*)-*t*-BuPHOX (**6**) as ligand in THF at 35 °C to afford the desired tetralone **3**

with moderate yield and good enantioselectivity (Table 1, entry 1). Screening of various solvents with the use of **6** as ligand¹³ revealed that benzene provides the highest levels of enantioselectivity and yield (entry 3). It was also found that the trifluoromethylated derivative of (*S*)-*t*-BuPHOX (i.e., 7)¹⁴ resulted in higher enantiomeric excesses and shorter reaction times, even with the use of only 1 or 2 mol % of catalyst (entries 4–6). Lowering the reaction temperature to 25 °C resulted in the formation of **3** in 94% ee, with the use of only 2 mol % of Pd₂(dba)₃ and 5 mol % of ligand **7**, albeit with a reduction in rate and yield (entry 7).

Having effectively set the absolute stereochemistry of the all-carbon quaternary center, C(9), we turned our efforts toward achieving the formal total synthesis of (+)-hamigeran B through the formation of the cyclopentene ring of 2 (Scheme 2). Ru-catalyzed cross metathesis¹⁵ of olefin 3 with methyl vinyl ketone using catalyst 8¹⁶ affords diketone 9 in 66% yield. Our initial attempts to form the cyclopentyl ring of the target structure (i.e., either enone 2 or alcohol 11) via traditional aldol condensation reactions resulted in complex mixtures of products, presumably due to nonselective enolization of diketone 10^{17} Hoping to utilize the α,β -unsaturation of enone 9 to ensure regioselective enolate formation,¹⁸ we attempted to directly form the cyclopentene ring from compound 9. CuHmediated,¹⁹ domino conjugate reduction-cyclization of 9 using Stryker's reagent²⁰ at 0 °C afforded desired ketoalcohol 11 as a single diastereomer, albeit in low yields (10-20%) with the remainder of the starting material converting to conjugate reduction product 10. It was found, however, that decreasing the temperature of the reaction to -40 °C resulted in an improved 52% yield of desired product 11 and only a 26% yield of conjugate reduction product 10. Alcohol 11 was then dehydrated with SOCl₂ and catalytic DMAP in pyridine²¹ to afford

(16) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. J. Am. Chem. Soc. **2000**, 122, 8168–8179.

(17) Diketone 10 was accessed by hydrogenation of enone 9. Subjecting 10 to a variety of aldol conditions led to complex product mixtures. For this reason, this strategy was not pursued further.



⁽¹⁸⁾ For a review, see: Huddleston, R. R.; Krische, M. J. Synlett 2003, 12–21.

(21) (a) Paquette, L. A.; Wang, H.-L.; Su, Z.; Zhao, M. J. Am. Chem. Soc. **1998**, *120*, 5213–5225. (b) Hagiwara, H.; Takeuchi, F.; Nozawa, M.; Hoshi, T.; Suzuki, T. Tetrahedron **2004**, *60*, 1983–1989.

^{(6) (}a) Trost, B. M.; Pissot-Soldermann, C.; Chen, I.; Schroeder, G. M. J. Am. Chem. Soc. **2004**, *126*, 4480–4481. (b) Trost, B. M.; Pissot-Soldermann, C.; Chen, I. Chem.—Eur. J. **2005**, *11*, 951–959.

⁽⁷⁾ Taber, D. F.; Tian, W. J. Org. Chem. 2008, 73, 7560-7564.

⁽⁸⁾ Miesch, L.; Welsch, T.; Rietsch, V.; Miesch, M. Chem.—Eur. J. 2009, 15, 4394-4401.

⁽⁹⁾ While preparing this manuscript, a synthesis of (\pm) -1 appeared; see: Lau, S. Y. W. *Org. Lett.* **2011**, *13*, 347–349.

⁽¹⁰⁾ For a review, see: Mohr, J. T.; Stoltz, B. M. Chem.—Asian J. 2007, 2, 1476–1491.

^{(11) (}a) Behenna, D. C.; Stoltz, B. M. J. Am. Chem. Soc. 2004, 126, 15044–15045.
(b) Mohr, J. T.; Behenna, D. C.; Harned, A. M.; Stoltz, B. M. Angew. Chem., Int. Ed. 2005, 44, 6924–6927.

⁽¹²⁾ von Ruzicka, L.; Hösli, H.; Hofmann, K. Helv. Chim. Acta 1936, 19, 370–377.

⁽¹³⁾ For list of solvents screened, see Supporting Information.

^{(14) (}a) Tani, K.; Behenna, D. C.; McFadden, R. M.; Stoltz, B. M. *Org. Lett.* **2007**, *9*, 2529–2531. (b) McDougal, N. T.; Streuff, J.; Mukherjee, H.; Virgil, S. C.; Stoltz, B. M. *Tetrahedron Lett.* **2010**, *51*, 5550–5554.

⁽¹⁵⁾ For a review, see: Grubbs, R. H. Tetrahedron 2004, 60, 7117-7140.

⁽¹⁹⁾ For a review, see: Deutsch, C.; Krause, N.; Lipshutz, B. H. Chem. Rev. 2008, 108, 2916–2927.

⁽²⁰⁾ Chiu, P.; Szeto, C.; Geng, Z.; Cheng, K. Org. Lett. 2001, 3, 1901–1903.

Scheme 2. Enantioselective Formal Synthesis of (+)-Hamigeran B



Table 1. Asymmetric Allylation of Allyl Enol Carbonate 5



^{*a*} Isolated yield. ^{*b*} Enantiomeric excess determined by chiral HPLC. ^{*c*} 1 mol % $Pd_2(dba)_3$ and 2.5 mol % 7. ^{*d*} 2 mol % $Pd_2(dba)_3$ and 5 mol % 7. ^{*e*} 25 °C.

enone **2**, which has previously been converted to hamigeran B in six steps.^{6,8} Thus our asymmetric, formal synthesis of (+)-hamigeran B was complete.

In summary, we have developed an expedient and concise formal synthesis of (+)-hamigeran B. A key tricyclic intermediate, **2**, en route to the synthesis of hamigeran B has been prepared in only five steps from known tetralone 4. The route features a key asymmetric, Pd-catalyzed decarboxylative allylic alkylation reaction that proceeds with excellent yield and enantioselectivity, allowing us to produce α -quaternary tetralone **3** in 94% ee. Ru-mediated cross metathesis of tetralone **3** with methyl vinyl ketone, followed by a CuH-mediated domino conjugate reduction-cyclization, established the core tricyclic skeleton of intermediate **2**. This general strategy (asymmetric alkylation, cross metathesis, reductive cyclization) is being applied to other bioactive natural products and will be reported in due course.

Acknowledgment. This publication is based on work supported by Award No. KUS-11-006-02, made by King Abdullah University of Science and Technology (KAUST). Additionally, the authors wish to thank NIH-NIGMS (R01 GM 080269-01), Abbott Laboratories, Amgen, the Gordon and Betty Moore Foundation, and Caltech for financial support and Materia, Inc. for the kind donation of catalyst 8. Dr. Douglas C. Behenna is gratefully acknowledged for assistance in the preparation of the manuscript.

Supporting Information Available. Experimental details and NMR spectra of all intermediates. This material is available free of charge via the Internet at http://pubs. acs.org.